Related Experiment Video
Updated: Jan 11, 2026
06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
19.9K
Cenobamate for Difficult-to-Treat Epilepsy - Selected Case Vignettes
Flavio Villani1, Fedele Dono2, Francesca Felicia Operto3
1Division of Clinical Neurophysiology and Epilepsy Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Neuropsychiatric Disease and Treatment
|November 12, 2025
Summary
Cenobamate shows promise for difficult-to-treat epilepsy, improving seizure control and quality of life in diverse patient groups. This novel antiseizure medication offers practical benefits beyond traditional clinical trials.
Area of Science:
- Neurology
- Pharmacology
Background:
- Epilepsy impacts millions globally, with specific challenges in elderly, pediatric, and drug-resistant cases.
- Current treatments often fall short for these complex subpopulations, highlighting unmet needs.
Purpose of the Study:
- To evaluate the role of cenobamate in managing complex epilepsy cases.
- To provide practical insights into cenobamate's use in diverse patient groups using real-world evidence.
Main Methods:
- Integration of real-world evidence from the EPI CONNECT project.
- Analysis of detailed case vignettes illustrating cenobamate's application.
- Exploration of cenobamate's dual mechanism of action.
Main Results:
- Cenobamate demonstrates potential for improved seizure control.
- It may simplify polytherapy and enhance tolerability in various epilepsy subpopulations.
- Case narratives highlight practical utility in challenging scenarios.
Conclusions:
- Cenobamate offers advantages for underserved epilepsy populations, including improved seizure control and quality of life.
- This research bridges clinical practice and research, advancing personalized treatment strategies.
- Further investigation into long-term efficacy and safety is warranted.
Related Concept Videos
01:30Electroconvulsive Therapy
835
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
835
01:14Antiepileptic Drugs: Glutamate Antagonists
876
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
876
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
616
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
616
01:13Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K